Meningitis Vaccine Project

Toward the end of epidemics

We’re working to stop meningitis in Africa

The Meningitis Vaccine Project (MVP) is a partnership between PATH and the World Health Organization. Our mission is to eliminate meningitis as a public health problem in sub-Saharan Africa through the development, testing, introduction, and widespread use of conjugate meningococcal vaccines. Our objectives are to:

  • Develop meningococcal conjugate vaccines that are appropriate for use in Africa.
  • Monitor the effectiveness and safety of the vaccines in controlled clinical trials.
  • Create pathways for the licensure of vaccines.
  • Ensure production in sufficient volume at a price that facilitates wide use in Africa.
  • Investigate innovative ways to finance the procurement of vaccines through local, country, and other global programs.
  • Introduce the vaccines through mass and routine immunization in synergy with other public health programs.

Read more about our work on the MVP website and on PATH’s website.

Our progress so far

Working with partners across four continents, MVP has developed an effective, affordable vaccine that targets the pathogen that causes most epidemics in sub-Saharan Africa: group A Neisseria meningitidis. The new vaccine, called MenAfriVac™, was developed in less than ten years and at one-tenth the cost of a typical vaccine.

Introduction of MenAfriVac® through mass immunization campaigns began in December 2010. By the end of that month, nearly 20 million people in Burkina Faso, Mali, and Niger—three of the hardest-hit countries in the region—had received the new vaccine. By June 2011, the three countries reported the lowest number of confirmed meningitis A cases ever recorded during an epidemic season. None of the reported cases occurred in vaccinated individuals.

MenAfriVac is a registered trademark of Serum Institute of India Ltd.

Banner photo: PATH.

Comments are closed.